NCI-2020-01859

NAUTIKA1: A MULTICENTER, PHASE II, NEOADJUVANT AND ADJUVANT STUDY OF MULTIPLE THERAPIES IN BIOMARKER-SELECTED PATIENTS WITH RESECTABLE STAGES IB?III NON-SMALL CELL LUNG CANCER

The NAUTIKA1 trial, a Phase II study conducted across multiple medical centers, focuses on patients with resectable stages IB-III non-small cell lung cancer, who are selected based on specific biomarkers. The study examines various treatments administered before and after surgery.

Phase II study: An advanced point of testing, where they're trying to confirm if a treatment works well.

non-small cell lung cancer: A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04302025

Clinical Trial Site: Columbia

To see all available clinical trials click here.